ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Sep 2019
Last Updated on 02 Sep 2019
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Ambrisentan 5 mg and 10 mg tablets for treating adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies:
    • Idiopathic PAH;
    • Heritable or familial PAH;
    • PAH associated with connective tissue disease;
    • Anorexigen-induced PAH; or
    • PAH associated with HIV infection.

Subsidy status
Ambrisentan 5 mg and 10 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF assistance does not apply to bosentan 62.5 mg and 125 mg tablets, and macitentan 10 mg tablet.

Endothelin receptor antagonists for pulmonary arterial hypertension (2 Sep 2019) PES Endothelin receptor antagonists for treating pulmonary arterial hypertension (Published 2 Sep 2019)